Samsung Seoul Hospital Achieves 1,500 Robotic Stomach Cancer Surgeries... 90% Five-Year Relative Survival Rate

22% of Stomach Cancer Surgeries Performed with Robots Last Year
Only Hospital in Korea to Introduce Gastrointestinal-Specialized "Da Vinci 5"

Samsung Seoul Hospital announced on September 2 that it has reached a cumulative total of 1,500 robotic surgeries for stomach cancer.

Samsung Seoul Hospital held a commemorative ceremony on the 28th of last month to celebrate reaching 1,500 cases of robotic stomach cancer surgery. In the front row from the left are Taesung Son, Deputy Director of Medical Services; Jiyoung Ahn, Professor of Gastrointestinal Surgery; Junho Lee, Head of Gastrointestinal Surgery; Jiyeon Lee, Director of the Stomach Cancer Center; Heecheol Kim, Director of the Cancer Hospital; and Sanghoon Ahn, Professor of Gastrointestinal Surgery. Photo by Samsung Seoul Hospital

As a result of its continuous expansion of minimally invasive surgeries aimed at reducing patients' pain, bleeding, and scarring, the hospital performed 256 robotic procedures out of the total 1,174 stomach cancer surgeries conducted last year, accounting for 22% of the cases.

The hospital expects the adoption of the latest "Da Vinci 5 (DV5)" robotic surgical system, dedicated solely to the Department of Gastrointestinal Surgery, to further accelerate the expansion of robotic surgeries. Samsung Seoul Hospital is currently the only hospital in Korea to have installed the DV5 exclusively for gastrointestinal surgery.

Junho Lee, Chief of the Department of Gastrointestinal Surgery at Samsung Seoul Hospital, said, "Introducing dedicated robotic equipment will improve surgical techniques that maintain both the treatment outcomes and the quality of life for stomach cancer patients. We will continue to focus on developing surgical methods that deliver even better treatment results for our patients."

Samsung Seoul Hospital forecasted that the growing use of robotic surgery will continue to improve outcomes for stomach cancer treatment. Currently, the five-year relative survival rate for stomach cancer patients at Samsung Seoul Hospital is 89.5%, which is higher than the Korean average of 78.6% and the U.S. average of 37.9%. The 90-day post-operative mortality rate is also just 0.42%, about half the average of 0.98% for tertiary general hospitals.

Jiyeon Lee, Director of the Stomach Cancer Center at Samsung Seoul Hospital (Hematology and Oncology), remarked, "By achieving a cumulative 1,500 robotic stomach cancer surgeries, we have once again demonstrated our global competitiveness. We will continue to pioneer new standards in stomach cancer care through accurate diagnosis and optimal treatment."

This content was produced with the assistance of AI translation services.